Jointown Pharmaceutical Group Co Ltd
SSE:600998

Watchlist Manager
Jointown Pharmaceutical Group Co Ltd Logo
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Watchlist
Price: 5.17 CNY
Market Cap: 26.1B CNY

Jointown Pharmaceutical Group Co Ltd
Cash from Investing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jointown Pharmaceutical Group Co Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Cash from Investing Activities
ÂĄ908.4m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sinopharm Group Co Ltd
HKEX:1099
Cash from Investing Activities
-ÂĄ3.2B
CAGR 3-Years
-50%
CAGR 5-Years
6%
CAGR 10-Years
2%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Cash from Investing Activities
-ÂĄ732.3m
CAGR 3-Years
64%
CAGR 5-Years
28%
CAGR 10-Years
8%
C
China National Medicines Corp Ltd
SSE:600511
Cash from Investing Activities
-ÂĄ2.5B
CAGR 3-Years
-138%
CAGR 5-Years
-113%
CAGR 10-Years
-45%
Huadong Medicine Co Ltd
SZSE:000963
Cash from Investing Activities
-ÂĄ1.6B
CAGR 3-Years
16%
CAGR 5-Years
-4%
CAGR 10-Years
-9%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Cash from Investing Activities
-ÂĄ156.5m
CAGR 3-Years
-4%
CAGR 5-Years
42%
CAGR 10-Years
4%
No Stocks Found

Jointown Pharmaceutical Group Co Ltd
Glance View

Market Cap
26.1B CNY
Industry
Health Care

In the sprawling landscape of the Chinese pharmaceutical industry, Jointown Pharmaceutical Group Co. Ltd. has emerged as a significant player, knitting together a vast network that facilitates the distribution of pharmaceutical products across the nation. Founded in 1999 and headquartered in Wuhan, Jointown has adeptly navigated the complexities of China's healthcare demands, becoming the country's largest privately-owned pharmaceutical wholesaler. The company’s operations span the procurement, distribution, and sale of a myriad of pharmaceutical products, medical devices, and healthcare supplies, effectively serving hospitals, clinics, and pharmacies through its extensive logistics and distribution channels. By leveraging cutting-edge technology to enhance its supply chain efficiency, Jointown ensures timely delivery and accessibility of medicines across urban and rural areas, thereby playing a pivotal role in supporting China's healthcare system. Jointown’s business model capitalizes on its robust logistical capabilities and comprehensive distribution network, which underpin its revenue streams. Through strategic partnerships with numerous domestic and international manufacturers, the company offers an impressive portfolio of pharmaceutical and healthcare products, maintaining a careful balance between proprietary and third-party offerings. This diversity in product offerings not only stabilizes its revenue base but also positions Jointown favorably in a highly competitive market. By continually expanding its e-commerce platforms and digital interfaces, the company fosters direct interaction with consumers, enhancing customer engagement and opening new revenue avenues. In essence, Jointown's prowess lies in its ability to integrate traditional distribution methods with innovative digital solutions, ensuring the company’s sustained growth and relevance in the ever-evolving pharmaceutical industry.

Intrinsic Value
18.42 CNY
Undervaluation 72%
Intrinsic Value
Price

See Also

What is Jointown Pharmaceutical Group Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
908.4m CNY

Based on the financial report for Sep 30, 2025, Jointown Pharmaceutical Group Co Ltd's Cash from Investing Activities amounts to 908.4m CNY.

What is Jointown Pharmaceutical Group Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-3%

The average annual Cash from Investing Activities growth rates for Jointown Pharmaceutical Group Co Ltd have been -3% over the past three years .

Back to Top